702 filings
Page 4 of 36
424B5
VTGN
VistaGen Therapeutics Inc
30 Jun 23
Prospectus supplement for primary offering
4:03pm
10-K
2023 FY
VTGN
VistaGen Therapeutics Inc
Annual report
28 Jun 23
5:11pm
8-K
VTGN
VistaGen Therapeutics Inc
28 Jun 23
Vistagen Provides Corporate Update and Reports Fiscal Year 2023 Financial Results
4:28pm
8-K
VTGN
VistaGen Therapeutics Inc
23 Jun 23
Other Events
8:35am
8-K
VTGN
VistaGen Therapeutics Inc
21 Jun 23
Other Events
4:43pm
8-K
VTGN
VistaGen Therapeutics Inc
13 Jun 23
Vistagen Announces European Patent Office Intention to Grant New
5:30pm
8-K
VTGN
VistaGen Therapeutics Inc
7 Jun 23
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 in Women Diagnosed with Menopausal Hot Flashes
4:33pm
8-K
VTGN
VistaGen Therapeutics Inc
6 Jun 23
Vistagen Announces Stockholder-Approved Reverse Stock Split
9:26am
8-K
VTGN
VistaGen Therapeutics Inc
1 Jun 23
Other Events
4:58pm
8-K
VTGN
VistaGen Therapeutics Inc
27 Apr 23
Regulation FD Disclosure
12:00am
8-K
VTGN
VistaGen Therapeutics Inc
19 Apr 23
Vistagen Presents New Fasedienol (PH94B) Research at 2023 Anxiety and Depression Association of America Conference
4:49pm
8-K
VTGN
VistaGen Therapeutics Inc
6 Apr 23
Vistagen Receives New European Patent for AV-101
4:31pm
8-K
VTGN
VistaGen Therapeutics Inc
30 Mar 23
Other Events
4:15pm
8-K
VTGN
VistaGen Therapeutics Inc
23 Mar 23
Vistagen Announces Positive Data in Fasedienol (PH94B) Phase 3
9:15am
EFFECT
VTGN
VistaGen Therapeutics Inc
22 Mar 23
Notice of effectiveness
12:15am
S-3/A
VTGN
VistaGen Therapeutics Inc
Shelf registration (amended)
17 Mar 23
4:28pm
CORRESP
VTGN
VistaGen Therapeutics Inc
17 Mar 23
Correspondence with SEC
12:00am
UPLOAD
VTGN
VistaGen Therapeutics Inc
9 Mar 23
Letter from SEC
12:00am
8-K
VTGN
VistaGen Therapeutics Inc
8 Mar 23
Other Events
5:25pm
8-K
VTGN
VistaGen Therapeutics Inc
7 Mar 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:40pm